Illumina vs Epic Which Should You Buy?

Illumina and Epic are two prominent companies in the healthcare industry, each specializing in different aspects of the field. Illumina is a leader in genetic sequencing technology, providing innovative solutions for researchers and healthcare professionals. On the other hand, Epic is a major player in the electronic health records market, offering integrated software systems for healthcare providers. Both companies have seen significant growth in recent years, but their stocks have performed differently due to various factors impacting their respective industries.

Illumina or Epic?

When comparing Illumina and Epic, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Illumina and Epic.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Illumina has a dividend yield of -%, while Epic has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Illumina reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Epic reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Illumina P/E ratio at -14.43 and Epic's P/E ratio at 0.00. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Illumina P/B ratio is 10.76 while Epic's P/B ratio is 0.00.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Illumina has seen a 5-year revenue growth of 0.26%, while Epic's is 0.00%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Illumina's ROE at -42.15% and Epic's ROE at 20.56%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $140.29 for Illumina and $0.00 for Epic. Over the past year, Illumina's prices ranged from $97.36 to $156.66, with a yearly change of 60.90%. Epic's prices fluctuated between $0.00 and $0.00, with a yearly change of 9900.00%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.